PCVX Live signals | Maximize Profits with Getagraph.com

BUY 18287 min ago

@ $74.02

Issued: 21 May 2024 @ 10:26

Return: -5.07%

Previous signal: May 20 - 11:01

Previous signal: Sell

Return: -1.06 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Stats
Today's Volume	420 403
Average Volume	643 379
Market Cap	7.65B
EPS	$0 ( 2024-05-13 )
Next earnings date	( $-1.170 ) 2024-06-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-16.38
ATR14	$0.0550 (0.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-23	Pickering Grant	Buy	15 000	Common Stock
2024-05-23	Pickering Grant	Sell	6 211	Common Stock
2024-05-23	Pickering Grant	Sell	8 789	Common Stock
2024-05-23	Pickering Grant	Sell	15 000	Stock Option (right to buy)
2024-05-20	Guggenhime Andrew	Sell	8 000	Stock Option (right to buy)

INSIDER POWER
33.42
Last 100 transactions
Buy: 771 551 \| Sell: 375 349

Volume Correlation

Long: 0.44 (neutral)

Short: 0.29 (neutral)

Signal:(70.835) Neutral

Vaxcyte Inc Correlation

10 Most Positive Correlations
ECOR	0.84
SLNO	0.809
MREO	0.808
MYGN	0.802

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Vaxcyte Inc Correlation - Currency/Commodity

0.58
( weak )

0.53
( weak )

0.00
( neutral )

0.20
( neutral )

-0.63
( weak negative )

Vaxcyte Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-10.17M (0.00 %)
EPS:	$-4.14

FY	2023
Revenue:	$0
Gross Profit:	$-10.17M (0.00 %)
EPS:	$-4.14

FY	2022
Revenue:	$0
Gross Profit:	$-9.20M (0.00 %)
EPS:	$-3.69

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.930

Financial Reports:

No articles found.

Vaxcyte Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Vaxcyte Inc

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Realtime updates for Vaxcyte Inc [PCVX]

Upcoming Earnings Alert

Vaxcyte Inc Options Data

Calls

Puts